PACIRA BIOSCIENCES, INC. (PCRX) Gross profit 2016–2025
PACIRA BIOSCIENCES, INC. (PCRX) annual gross profit history from SEC filings — each fiscal year as reported.
$576.7MFY2025 · since FY2016: $160.0M → $576.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $576.7M | +8.7% |
| FY2024 | $530.5M | +8.2% |
| FY2023 | $490.3M | +4.9% |
| FY2022 | $467.5M | +16.5% |
| FY2021 | $401.3M | +28.5% |
| FY2020 | $312.3M | +0.0% |
| FY2019 | $312.2M | +27.1% |
| FY2018 | $245.6M | +25.0% |
| FY2017 | $196.4M | +22.8% |
| FY2016 | $160.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PCRX financial trends
PCRX RevenuePCRX Net incomePCRX Net marginPCRX Gross marginPCRX Operating incomePCRX Operating marginPCRX Operating cash flowPCRX Free cash flowPCRX Capital expendituresPCRX Return on equityPCRX Stock buybacksPCRX Dividends paidPCRX Total assetsPCRX Total liabilitiesPCRX Shareholders’ equityPCRX overview →